The independence of NEDD9 from the BCR (and BCL-2) encourages to further explore targeting the NEDD9 signaling axis as an alternative approach to prevent CLL homing, particularly in cases resistant to BCR inhibitors or venetoclax. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.